HK1219533A1 - 蛋白质组学ipf标志物 - Google Patents

蛋白质组学ipf标志物 Download PDF

Info

Publication number
HK1219533A1
HK1219533A1 HK16107519.9A HK16107519A HK1219533A1 HK 1219533 A1 HK1219533 A1 HK 1219533A1 HK 16107519 A HK16107519 A HK 16107519A HK 1219533 A1 HK1219533 A1 HK 1219533A1
Authority
HK
Hong Kong
Prior art keywords
ipf
proteomic
markers
biomarkers
prediction
Prior art date
Application number
HK16107519.9A
Other languages
English (en)
Chinese (zh)
Inventor
Karl Kossen
Xiaoli Qin
Sharleen R. LIM
Scott D. Seiwert
Donald Ruhrmund
Original Assignee
Intermune, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermune, Inc. filed Critical Intermune, Inc.
Publication of HK1219533A1 publication Critical patent/HK1219533A1/zh

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
HK16107519.9A 2013-03-15 2014-03-14 蛋白质组学ipf标志物 HK1219533A1 (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361801476P 2013-03-15 2013-03-15
US201361801290P 2013-03-15 2013-03-15
US61/801,476 2013-03-15
US61/801,290 2013-03-15
US201361874947P 2013-09-06 2013-09-06
US61/874,947 2013-09-06
PCT/US2014/029392 WO2014144821A1 (en) 2013-03-15 2014-03-14 Proteomic ipf markers

Publications (1)

Publication Number Publication Date
HK1219533A1 true HK1219533A1 (zh) 2017-04-07

Family

ID=51537804

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16107519.9A HK1219533A1 (zh) 2013-03-15 2014-03-14 蛋白质组学ipf标志物

Country Status (11)

Country Link
US (1) US9726677B2 (https=)
EP (1) EP2972392A4 (https=)
JP (1) JP2016519763A (https=)
KR (1) KR20150130408A (https=)
CN (1) CN105122068A (https=)
BR (1) BR112015023699A2 (https=)
CA (1) CA2901384A1 (https=)
HK (1) HK1219533A1 (https=)
MX (1) MX2015012778A (https=)
RU (1) RU2015144149A (https=)
WO (1) WO2014144821A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
US8669057B2 (en) 2009-05-07 2014-03-11 Veracyte, Inc. Methods and compositions for diagnosis of thyroid conditions
RU2015144149A (ru) 2013-03-15 2017-04-21 Интермьюн, Инк. Протеомные маркеры илф
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
EP3215170A4 (en) 2014-11-05 2018-04-25 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
WO2018191751A1 (en) * 2017-04-14 2018-10-18 Arizona Board Of Regents On Behalf Of The University Of Arizonia Compositions and methods for treating pulmonary fibrosis
US10975167B2 (en) 2017-04-14 2021-04-13 Arizona Board Of Regents On Behalf Of The University Of Arizona Method to reduce pulmonary arterial hypertension by administering inhibitors of nicotinamide phosphoribotransferase
CN107677835B (zh) * 2017-09-26 2019-08-09 上海市肺科医院 一种ae-ipf的蛋白标记物及其应用
CN113260863A (zh) * 2018-08-17 2021-08-13 豪夫迈·罗氏有限公司 用于心房纤颤的评价中的循环bmp10 (骨形态发生蛋白10)
JP7440042B2 (ja) * 2018-10-29 2024-02-28 国立大学法人 東京医科歯科大学 間質性肺炎患者の呼吸機能の低下リスクに関する情報を取得する方法及びその利用
JP7300642B2 (ja) * 2019-06-14 2023-06-30 国立大学法人浜松医科大学 特発性肺線維症の予後予測方法
CN110333358A (zh) * 2019-06-24 2019-10-15 浙江大学 一种急性肺损伤小鼠肺脏全免疫细胞特征图谱的建立方法
JP7614477B2 (ja) * 2019-08-02 2025-01-16 国立医薬品食品衛生研究所長 間質性肺炎のタンパク質診断バイオマーカー
EP4117659A4 (en) * 2020-03-13 2024-04-03 Puretech Lyt 100, Inc. Methods of treating respiratory disease with deupirfenidone
CN115702351B (zh) * 2020-04-17 2026-03-31 国立医药品食品卫生研究所长 重症药疹的蛋白质诊断生物标记物
CN113607955A (zh) * 2020-09-16 2021-11-05 广州中医药大学顺德医院(佛山市顺德区中医院) 新型冠状病毒肺炎分期与疗效评估细胞因子标志物及其应用
CN113533750A (zh) * 2020-10-22 2021-10-22 广州中医药大学顺德医院(佛山市顺德区中医院) 一种区分新型冠状病毒肺炎患者与健康者的系统
US20250122293A1 (en) * 2021-09-07 2025-04-17 Fnct Biotech, Inc. Csf3r as biomarker and therapeutic target for pulmonary fibrosis
WO2023081299A1 (en) * 2021-11-05 2023-05-11 Spiritus Therapeutics, Inc. A purified enriched population exosomes derived from individuals with a chronic progressive lung disease for noninvasive detection, staging, and medical monitoring of disease progression
CN114563562A (zh) * 2022-03-01 2022-05-31 复旦大学附属中山医院 Prdx6联合铁离子检测在ards进程监测中的应用
KR102907646B1 (ko) * 2022-08-19 2026-01-05 울산대학교 산학협력단 특발성 폐섬유증 환자의 진단 및 경과예측용 호기 바이오마커
CN119947728A (zh) * 2022-09-28 2025-05-06 勃林格殷格翰国际有限公司 生物标志物在用pde4b抑制剂治疗纤维化病症中的用途
CN117025745B (zh) * 2022-11-18 2024-02-23 中国医学科学院北京协和医院 分子标志物在诊断干燥综合征中的应用
WO2026069490A1 (ja) * 2024-09-25 2026-04-02 国立大学法人大阪大学 進行性肺線維症診断用バイオマーカー、該バイオマーカーを用いた進行性肺線維症の検査方法及びそれらの利用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5637459A (en) 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
US6019988A (en) 1996-11-18 2000-02-01 Bristol-Myers Squibb Company Methods and compositions for enhancing skin permeation of drugs using permeation enhancers, when drugs and/or permeation enhancers are unstable in combination during long-term storage
JP4406206B2 (ja) * 2001-04-24 2010-01-27 バイエル コーポレーション ヒトｔｉｍｐ−１抗体
AUPR638101A0 (en) * 2001-07-13 2001-08-09 Bioa Pty Limited Composition and method for treatment of disease
JP2003238592A (ja) * 2001-12-13 2003-08-27 Japan Tobacco Inc 組織及び血管の再生のための医薬及びその方法
US20040219142A1 (en) 2002-07-19 2004-11-04 Abbott Laboratories S.A. Treatment of skin and nail disorders using TNFalpha inhibitors
US7888485B2 (en) * 2003-03-26 2011-02-15 Georgetown University Anti-pleiotrophin antibodies and methods of use thereof
US20060211752A1 (en) * 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
EP1626279B1 (en) * 2004-08-12 2008-04-16 Roche Diagnostics GmbH Method for diagnosing liver fibrosis
CN101160528A (zh) * 2005-02-14 2008-04-09 惠氏公司 Il17-f在诊断和治疗气道炎症中的用途
EP1757940A1 (en) * 2005-08-26 2007-02-28 Cézanne S.A.S. In vitro method for diagnosing and monitoring renal cell carcinoma (RCC) using MMP-7 as humoral biomarker for RCC
US20110129845A1 (en) * 2007-01-29 2011-06-02 Crc For Asthma And Airways Ltd. Method of diagnosis
WO2009028158A1 (en) * 2007-08-24 2009-03-05 Oncotherapy Science, Inc. Dkk1 oncogene as therapeutic target for cancer and a diagnosing marker
WO2010028274A1 (en) 2008-09-05 2010-03-11 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Marker panels for idiopathic pulmonary fibrosis diagnosis and evaluation
US8568996B2 (en) * 2008-10-21 2013-10-29 University of Pittsburgh—of the Commonwealth System of Higher Education MMP activation peptide detection in biological samples
WO2010083392A2 (en) * 2009-01-16 2010-07-22 The Ohio State University Research Foundation Ets-2 biomarkers for fibrotic diseases and uses thereof
EP2403880A1 (en) * 2009-03-05 2012-01-11 Tripath Imaging, Inc. Matrix metalloproteinase-7 (mmp-7) monoclonal antibodies and methods for their use in the detection of ovarian cancer
WO2010111625A1 (en) * 2009-03-27 2010-09-30 Zymogenetics, Inc. Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
AU2010283997B2 (en) * 2009-08-21 2015-04-09 Gilead Biologics, Inc. Methods and compositions for treatment of pulmonary fibrotic disorders
EP2496944A2 (en) * 2009-11-05 2012-09-12 Novartis AG Biomarkers predictive of progression of fibrosis
WO2011091270A2 (en) * 2010-01-21 2011-07-28 The Regents Of The University Of Michigan Biomarkers for lung disease monitoring
AU2012312515A1 (en) * 2011-09-19 2014-03-13 Genentech, Inc. Combination treatments comprising c-met antagonists and B-raf antagonists
RU2015144149A (ru) 2013-03-15 2017-04-21 Интермьюн, Инк. Протеомные маркеры илф

Also Published As

Publication number Publication date
WO2014144821A1 (en) 2014-09-18
CN105122068A (zh) 2015-12-02
EP2972392A1 (en) 2016-01-20
US20140286929A1 (en) 2014-09-25
EP2972392A4 (en) 2017-03-22
RU2015144149A (ru) 2017-04-21
MX2015012778A (es) 2016-01-20
BR112015023699A2 (pt) 2017-07-18
JP2016519763A (ja) 2016-07-07
CA2901384A1 (en) 2014-09-18
KR20150130408A (ko) 2015-11-23
US9726677B2 (en) 2017-08-08

Similar Documents

Publication Publication Date Title
HK1219533A1 (zh) 蛋白质组学ipf标志物
EP3244766A4 (en) Sole structure with bottom-loaded compression
CA3292296A1 (en) Intelligent wireless communications for continuous analyte monitoring
EP3397836A4 (en) GEODIRECTION BASED ON AN AUTOMATED PREDICTION OF WELL PERFORMANCE
EP3273694A4 (en) Image decoding method for performing intra prediction and device thereof, and image encoding method for performing intra prediction and device thereof
IL251571A0 (en) Variable proteins comprising the cry1da1 amino acid sequence are activated by lepidopteran
ZA201808503B (en) Diorganylphosphinic acid salts, method for the production thereof and the use thereof
EP3273695A4 (en) Image decoding method for performing intra prediction and device thereof, and image encoding method for performing intra prediction and device thereof
EP3281467A4 (en) Epdcch search space determination
EP3286744A4 (en) Process instrumentation with wireless configuration
EP3099138A4 (en) Multi-mode wireless terminal
EP3257293A4 (en) Pre-caching on wireless access point
EP3136800A4 (en) Method for updating rplmn information, and user equipment
WO2014125506A3 (en) A process for the preparation of ivacaftor and its intermediates
GB2562897B (en) Lossless data compression
HUE049810T2 (hu) Többrégiós keresési tartomány blokk elõrebecslési módhoz kijelzés folyam tömörítéshez (DSC)
ZA201801498B (en) An improved refolding process for antibody's fragments
EP3123942A4 (en) Ovulation day prediction program and ovulation day prediction method
EP3253781A4 (en) Modified dkk2 protein, nucleic acid encoding the same, preparation method thereof, and use thereof
EP3244968A4 (en) Combination therapy for pulmonary hypertension
EP3236554A4 (en) Demand power prediction device, demand power prediction method, and program
EP3392263A4 (en) POLYPEPTIDE COMPOUND, METHOD FOR PREPARING THE SAME, AND USE THEREOF
EP3329922A4 (en) SECRETAGOGUE OF GLP-1
EP3284397A4 (en) Biometric information monitor
EP3130715A4 (en) Anti-seismic, insulating construction element